Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features

BACKGROUND: Bone-destructive disease treatments include bisphosphonates and antibodies against the osteoclast differentiator, RANKL (aRANKL); however, osteonecrosis of the jaw (ONJ) is a frequent side-effect. Current models fail to explain the restriction of bisphosphonate (BP)-related and denosumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehrhan, Falk, Hyckel, Peter, Ries, Jutta, Stockmann, Phillip, Nkenke, Emeka, Schlegel, Karl A, Neukam, Friedrich W, Amann, Kerstin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973937/
https://www.ncbi.nlm.nih.gov/pubmed/20942943
http://dx.doi.org/10.1186/1479-5876-8-96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973937/
https://www.ncbi.nlm.nih.gov/pubmed/20942943
http://dx.doi.org/10.1186/1479-5876-8-96

Ejemplares similares